论文信息 - Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia - 字舞流文

Ibrutinib dose intensity in high‐risk chronic lymphocytic leukemia

This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.

F. Cavalli | D. Rossi | G. Gaidano | R. Moia | F. Passamonti | J. Passweg | M. Merli | A. Frustaci | M. Deodato | A. Tedeschi | E. Zucca | S. Rasi | G. Stussi | V. Gattei | L. Laurenti | B. Gerber | M. Pirosa | P. Ghia | L. Scarfò | A. Condoluci | L. Terzi di Bergamo | C. Deambrogi | V. Spina | A. Bruscaggin | P. Bulian | F. Autore | D. Piffaretti | G. Forestieri | K. Pini | J. Marques de Almeida | Michael Gregor | Gaby Fahrni | R. Mattarucchi | D. Gussetti | Annagiulia Zanatta | M. Salehi

[1] D. Rossi,et al. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab , 2021, Blood advances.

[2] A. Wiestner,et al. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] T. Shanafelt,et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice , 2020, Cancer medicine.

[4] A. Wiestner,et al. Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL. , 2019, Blood.

[5] R. Rosenquist,et al. Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort , 2018, Haematologica.

[6] F. Hernandez-Ilizaliturri,et al. Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL) , 2018, Leukemia & lymphoma.

[7] Xuelin Huang,et al. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. , 2018, Blood.

[8] B. Cheson,et al. Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial , 2018, American journal of hematology.

[9] J. Byrd,et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. , 2018, Blood.

[10] C. Nabhan,et al. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced‐dose ibrutinib: results from a multi‐centre study , 2018, British journal of haematology.

[11] J. Byrd,et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. , 2017, Blood.

[12] J. Zaucha,et al. Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG) , 2017, Leukemia & lymphoma.

[13] A. Österborg,et al. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group , 2016, Haematologica.

[14] U. C. Forum. Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients , 2016, Haematologica.